Biobot Surgical develops minimally invasive robotic systems that target and accurately position biopsy needles to provide comprehensive prostate coverage. Its technology is designed to help physicians detect prostate cancer earlier and to give clinicians confidence to enroll patients in active surveillance programs. The company emphasizes robot-guided biopsy targeting and precise needle placement as its core product capability. The article reports that Biobot Surgical recently completed a financing event. Investors and financial details are limited in the report. No operating metrics or use-of-proceeds details were disclosed in the article. Biobot Surgical is a Singapore-based developer of minimally-invasive robotic diagnostic solutions. The company secured $5.2 million in new investment last month. The capital came from a group of investors. That investor group included a vehicle backed by businessman Tony Tan Choon Keat. The raise also saw participation from long-time backer ZIG Ventures. No additional operating metrics or financial details were provided in the article.

Total raised

$23M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2024